Nextcure, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

5 Mar 2026

NXTC

10-K: NextCure Faces Going Concern Amid ADC Pipeline Push

NextCure, Inc. reported continued net losses and a going concern warning for 2025, while advancing its lead antibody-drug conjugate candidates and securing additional financing.

NASDAQ

7 Mar 2025

NXTC

Nextcure, INC

10-K: NextCure's 2024 10-K Filing: Focus on LNCB74 and Strategic Partnerships

NextCure's 2024 10-K filing highlights the company's focus on advancing LNCB74, a B7-H4 targeted ADC, and pursuing strategic partnerships for other programs.

NASDAQ

21 Mar 2024

NXTC

Nextcure, INC

10-K: NextCure Prioritizes Pipeline, Pauses Manufacturing in Strategic Restructuring

NextCure is focusing on its lead programs, NC410 and LNCB74, while pausing manufacturing and seeking partnerships for other assets to extend its cash runway.